Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: Two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials

The Lancet Respiratory Medicine

Volumn 3, Issue 5, 2015, Pages 367-376

  Kerstjens, Huib A M ^a   Casale, Thomas B ^b   Bleecker, Eugene R ^c   Meltzer, Eli O ^d   Pizzichini, Emilio ^e   Schmidt, Olaf ^f   Engel, Michael ^g   Bour, Loek ^g   Verkleij, Cynthia B ^g   Moroni Zentgraf, Petra ^g   Bateman, Eric D ^h  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^e FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^f KPPK GmbH   (Germany)

^g BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^h UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUORINATED HYDROCARBON; LONG ACTING DRUG; PLACEBO; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT; SALMETEROL XINAFOATE;

ADD ON THERAPY; ADULT; AGED; AIRWAY OBSTRUCTION; ALLERGIC RHINITIS; ARTICLE; ASTHMA; BEDTIME DOSAGE; BRONCHITIS; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; HYPERTENSION; INHALER; LUNG FUNCTION TEST; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MONOTHERAPY; MORNING DOSAGE; OROPHARYNX PAIN; PEAK EXPIRATORY FLOW; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SINUSITIS; SMOKING; THIRST; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; DRUG COMBINATION; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; ASTHMA; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; SALMETEROL XINAFOATE; TIOTROPIUM BROMIDE; TREATMENT OUTCOME;

EID: 84929030264     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00031-4     Document Type: Article

References (27)

1. Global strategy for asthma management and prevention Global Initiative for Asthma, (accessed Sep 9, 2014). http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Jun11.pdf.
2. Chapman KR, Boulet LP, Rea RM, Franssen E Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J 2008, 31:320-325.
3. Partridge MR, van der Molen T, Myrseth SE, Busse WW Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006, 6:13.
4. Rabe KF, Adachi M, Lai CKW, et al. Worldwide severity and control of asthma in children and adults: the global Asthma Insights and Reality surveys. J Allergy Clin Immunol 2004, 114:40-47.
5. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004, 170:836-844.
6. Chowdhury BA, Dal Pan G The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010, 362:1169-1171.
7. Kerstjens HAM, Disse B, Schröder-Babo W, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol 2011, 128:308-314.
8. Kerstjens HAM, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012, 367:1198-1207.
9. Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010, 363:1715-1726.
10. Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol 2011, 128:315-322.
11. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999, 14:902-907.
12. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009, 180:59-99.
13. Note for guidance on the clinical investigation of medicinal products in the treatment of asthma European Medicines Agency Committee for Proprietary Medicinal Products, (accessed Sep 9, 2014). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003555.pdf.
14. Westby MJ, Benson MK, Gibson PG Anticholinergic agents for chronic asthma in adults. Cochrane Database Syst Rev 2004, 3. CD003269.
15. Nathan RA, Nolte H, Pearlman DS Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 μg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids. Allergy Asthma Proc 2010, 31:269-279.
16. Meltzer EO, Kuna P, Nolte H, Nayak AS, LaForce C Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. Eur Respir J 2012, 39:279-289. on behalf of the P04073 Study Investigators.
17. Noonan M, Rosenwasser LJ, Martin P, O'Brien CD, O'Dowd L Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Drugs 2006, 66:2235-2254.
18. Corren J, Korenblat PE, Miller CJ, O'Brien CD, Mezzanotte WS Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clin Ther 2007, 29:823-843.
19. Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50 μg and fluticasone propionate 250 μg in the Diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000, 161:527-534.
20. Pearlman DS, Peden D, Condemi JJ, et al. Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma. J Asthma 2004, 41:797-806.
21. Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000, 105:1108-1116.
22. Bateman ED, Esser D, Chirila C, et al. Systematic review and meta-analysis of the magnitude of the effect on the AQLQ and ACQ in asthma clinical trials. European Respiratory Society Annual Congress; Barcelona, Spain; Sept 7-11, 2013. P4113.
23. Beeh KM, Moroni-Zentgraf P, Ablinger O, et al. Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma. Respir Res 2014, 15:61.
24. Peters SP, Bleecker ER, Kunselman SJ, et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. J Allergy Clin Immunol 2013, 132:1068. 74.e1.
25. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554.
26. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011, 364:1093-1103.
27. Vogelberg C, Engel M, Moroni-Zentgraf P, et al. Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study. Respir Med 2014, 108:1268-1276.